newsfilter
← Latest News
Earnings Call Transcripts·

JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - CORBUS PHARMACEUTICALS HOLDINGS INC

  • Explicit Guidance:

    • BLA Submission: Anticipated around the second half of 2028 for the Nectin-4 ADC (Corbus), contingent on sufficient ORR data and follow-up (Target: ORR >30% in 2nd line; >50% in 1st line).
    • Obesity Efficacy Target: Expectation of >10% total body weight loss at 52 weeks, positioning efficacy between oral orfaglipron and oral semaglutide (Wegovy).
  • Business-Segment Outlook:

    • Oncology (Nectin-4 ADC):
      • 2nd Line Head and Neck: TEMPO-1 Phase 3 study is active; primary endpoint strategy mirrors Genmab (accelerated approval based on ORR, final approval based on OS). Control arm ORR assumption ~20%; target ORR >30% is clinically desirable and actionable.
      • 1st Line Head and Neck: Target ORR >50% to coexist with competitors; enrollment expected to be overwhelmingly complete before PITO (Pembrolizumab) becomes a frontline option.
      • Cervical Cancer (China Partner): CSBC (China) is initiating a Phase 3 study; regimen is 2.4 mg Q2W (vs. 3.6 mg Q3W in Corbus), reflecting a China FDA peculiarity.
    • Obesity (CB1 Inverse Agonist):
      • Pipeline Status: Phase 1B 250-patient study completed; feedback indicates KOL enthusiasm for efficacy (orthogonal to GLP-1) and safety (no psychiatric concerns, mild GI effects).
      • Combination Strategy: High interest from KOLs in combining with orfaglipron; future studies will assess 52-week data.
  • Market and Competitive Outlook:

    • Competitive Landscape (Oncology):
      • PETO (Pembrolizumab): Posited as a 1st-line drug; not expected to be a 2nd-line competitor for Corbus due to regulatory pathway constraints, effectively removing PETO from the 2nd-line space.
      • Peixis (PXD-101): Different mechanism (tumor microenvironment/bystander effect); targets HPV-negative population where Corbus does not compete, though Peixis has a broad label. Corbus is "meaningfully ahead" with an active registrational Phase 3 vs. Peixis' earlier stage.
      • KOL Barriers: 2nd line for oropharyngeal cancer described as a "desert" with few options; 1st line requires >50% ORR to demonstrate a delta sufficient to coexist with existing therapies.
    • Safety Differentiation: Corbus ocular toxicity (keratitis/dry eye) is described as temporary, resolvable, and managed via drops/interruptions, contrasting sharply with irreversible peripheral neuropathy associated with PADCET.
  • Macro / Industry Outlook:

    • Regulatory Environment: FDA alignment confirmed for accelerated approval pathway based on ORR with OS confirmation; China FDA has specific regimen requirements for partner programs.
    • Patient Population: Focus on oropharyngeal cancer (85% HPV positive), but study population includes HPV-negative patients to reflect real-world diversity; retrospective P16 stratification used.
  • Strategic Initiatives:

    • Data Releases:
      • 2026: Anticipated OS data updates and robust direction for 2nd-line submission trigger.
      • Next Year: Plans to update durability data for 2nd-line oral pharyngeal patients.
    • Capacity/Operations: Current Phase 3 enrollment pace expected to complete prior to competitor 1st-line readouts.
    • Partnerships: Collaboration with CSBC in China remains active; data reassurance from their Phase 3 cervical cancer program.
  • Risks and Headwinds to Outlook:

    • Ocular Toxicity: Potential for treatment interruptions (approx. 1/3 of patients) and dose reductions, though management strategies are established and impacts are deemed not "particularly impactful."
    • Competitive Dynamics: 1st-line success of competitors (PETO) could impact Corbus' ability to demonstrate a sufficient efficacy delta in the front-line setting.
    • Regulatory Pathway: Accelerated approval carries the risk of requiring robust OS data for full approval; failure to meet ORR thresholds (>30% 2nd line, >50% 1st line) would delay or prevent submission.
    • Patient Stratification: Potential dilution of treatment effect by HPV-negative patients in the oropharyngeal cohort, though early data suggests value in this population.
  • Management Tone on the Future:

    • Confidence: High confidence in the "sensible and clever" statistical strategy emulating Genmab; described the 2nd-line setting as a "huge opportunity" due to lack of current treatments.
    • Strategic Hedges: Emphasis on the distinct mechanisms of action to avoid direct head-to-head competition with Peixis in HPV-negative space; reliance on "meaningfully ahead" status in Phase 3 execution.
    • Sentiment: Optimistic regarding the "immensely informative" and "uniform" KOL feedback on the obesity asset; views the 52-week data as a key inflection point.
  • Miscellaneous:

    • Drug Naming: Nectin-4 ADC assigned official name "sutantitag invidotin" (nicknamed "sutai").
    • Safety Profile: Irritability in obesity program observed at start of treatment (mostly 20 mg), resolves immediately upon discontinuation, mild, not dose-dependent, and caused no discontinuations.
    • Clinical Context: 2nd-line oropharyngeal cancer treatment described as a "medical tragedy" with 50% of eligible patients in the US electing no treatment.
Company
CORBUS PHARMACEUTICALS HOLDINGS INC
Keywords
CORBUS PHARMACEUTICALS HOLDINGS INC